VERA Vera Therapeutics Inc
Company Analysis
Latest News
🔴 Vera Therapeutics is trading 4.47% down today as major U.S. indexes fall
Vera Therapeutics is trading 4.47% down now at $33.48, with the decline appearing primarily aligned with broader risk-off sentiment. - No clear...
🟢 Vera Therapeutics is trading 5% up today after inflation data matched expectations
Vera Therapeutics is trading at $35.20, up +4.76% on September 11, 2026, alongside broad market gains after August inflation data matched expectations. - The...
🔴 Vera Therapeutics is trading 4.25% down today as U.S. equities declined
Vera Therapeutics is trading 4.25% down at $33.78 as broad risk-off pressure weighed on U.S. equities on September 9, 2026. - No clear company-specific...
🔴 Vera Therapeutics is trading 4.07% down today with no company-specific catalyst identified
Vera Therapeutics is trading at $35.32 (-4.07%) with no new company-specific announcement identified for August 27, 2026. - Recent gains followed 4.37%,...
🟢 Vera Therapeutics is trading 4.13% up today on biotech-sector strength
Vera Therapeutics is trading at $36.74, up +4.13%, primarily on biotech-sector strength. - No new company-specific announcement was identified for August 26,...
🟢 Vera Therapeutics is trading 4.9% up today on biotech-sector strength
Vera Therapeutics is trading 4.9% up now at $35.35, supported by biotechnology strength and gains in major U.S. indexes. - No new company-specific catalyst...
🟢 Vera Therapeutics is trading 7.14% up today
Vera Therapeutics is trading 7.14% up at $34.53, but no catalyst has been confidently identified. - No company-specific announcement, filing, analyst action,...
🟢 Vera Therapeutics is trading 4.06% up today amid a broader biotech rally
Vera Therapeutics is trading 4.06% up now at $32.53 as biotechnology shares continue recovering after recent sector volatility. - No new company-specific...
🔴 Vera Therapeutics falls 4.3% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Vera's FDA Review Win Sends Shares Surging — But Can a $425,000 Drug Survive a Crowded Kidney Market?
Shares jumped 10.3% to $31.86 after the FDA published an integrated review describing a favorable safety-and-efficacy profile for Vera Therapeutics' recently...
🟢 Vera Therapeutics is trading 10% up today after FDA review signals Trutakna’s competitive profile
Vera Therapeutics is trading 10.28% up now at $31.86 after the FDA published an integrated review describing a favorable profile for Trutakna, its recently...
🟢 Vera Therapeutics surges 10% after FDA publishes favorable review of Trutakna and investors reassess Q2 results
Vera Therapeutics (VERA) stock is trading 9.93% up at $31.76 today. - The surge follows the FDA's publication of a favorable integrated review of Trutakna, its...
🟢 Vera Therapeutics is trading 6% up today in pre-market following stronger August 13 U.S. market performance
Vera Therapeutics is trading at $30.54, up +5.71%, in pre-market on August 14, 2026, likely reflecting broader risk-on sentiment following stronger August 13,...
🟢 Vera Therapeutics is trading 11% up today in after-hours trading amid broader risk-on market sentiment
Vera Therapeutics is trading at $32.01 (+10.80%) after broader risk-on sentiment likely contributed to the gain. - The S&P 500 rose 0.72% and Nasdaq advanced...
🟢 Vera Therapeutics is trading 5.2% up in after-hours trading amid broader risk-on sentiment
Vera Therapeutics is trading at $30.38, up 5.16% in after-hours trading, in a move consistent with stronger risk appetite; no new company-specific announcement...
🟢 Vera Therapeutics is trading 6% up today in pre-market after narrower-than-expected Q2 loss
Vera Therapeutics is trading 5.65% up at $32.00 after its August 10, 2026, second-quarter update highlighted a narrower-than-expected $1.52-per-share loss. -...
🔴 Vera Therapeutics is trading 4.43% down today after a $109.5 million second-quarter net loss
Vera Therapeutics is trading 4.43% down at $30.18 after investors weighed its August 10 earnings report, which showed a $109.5 million second-quarter net loss...
Vera Therapeutics Beat Estimates and Launched Its First Drug — But Can a $425,000 Kidney Therapy Carve Out Space in a Six-Drug Market?
Shares jumped 6.1% to $33.50 after Vera Therapeutics posted second-quarter results that cleared a low bar while giving investors their first glimpse of life as...
🟢 Vera Therapeutics is trading 6% up in pre-market after second-quarter EPS beat
Vera Therapeutics is trading at $33.50 (+6.08%) after reporting second-quarter EPS of -$1.52 versus the -$1.60 analyst expectation. - Began the TRUTAKNA...
Vera Therapeutics beats second quarter 2026 EPS estimates as TRUTAKNA commercial launch begins
Vera Therapeutics reported a second quarter 2026 net loss of $109.5 million, or $1.52 per share, which narrowed from the $1.60 loss expected by analysts. While...